Treatment with SGLT2 inhibitors significantly lowered urinary AGT levels and renal AGT expression in animal models of type 2 diabetes (Woods et al., 2019), and a similar tendency was observed in patients with type 2 diabetes (Yoshimoto et al., 2017). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.